NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026

NextCure, Inc.

Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.
Workforce reduction ~37%; internal GMP manufacturing paused; one-time restructuring charges ~$0.8M expected in Q2 2024.
NC410 combo: 42.8% ORR (3 PRs in 7 evaluable ovarian patients); CRC cohort 10.5% ORR (2/19), median PFS 8.1 months.
LNCB74 (B7-H4 ADC) IND planned by year-end 2024; cost-sharing with LegoChem Biosciences.
Cash runway now expected into second half of 2026 following restructuring and cost reductions.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NextCure, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

316 earnings releases filed in the last 30 days. Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-003671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.